Compare Huntington Bancshares Incorporated (HBAN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Sana Biotechnology Inc — how do they compare? Huntington Bancshares Incorporated trades at $18.13 (market cap $36.62B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Huntington Bancshares Incorporated is far larger — about 41.9× Sana Biotechnology Inc's market cap, and Huntington Bancshares Incorporated pays a 3.43% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HBAN | SANA | |
|---|---|---|
Market Cap | $36.62B | $873.84M |
Sector | Financials | Health |
52-Week High | $19.27 | $5.92 |
52-Week Low | $15.02 | $2.68 |
Dividend Yield | 3.43% | — |
Enterprise Value | — | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.17, down 0.44% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 13.9 and a net income margin of 25.13%, with Q2 2026 earnings expected at $0.39 per share. Recent news highlights the upcoming earnings report on July 23, 2026, and positive developments from the company's Texas expansion.
The outlook for HBAN is positive, driven by earnings growth potential and analyst consensus of $20.25 price target. Key risks include integration challenges from acquisitions and competitive pressures in regional banking markets. The stock presents a value opportunity with solid fundamentals, though investors should monitor expense management and loan growth trends.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
